1 | multicenter | 9,074 |
2 | multicentre | 3,200 |
3 | single-center | 1,404 |
4 | multi-center | 761 |
5 | multi-centre | 746 |
6 | multinational | 700 |
7 | multisite | 553 |
8 | single-centre | 455 |
9 | two-arm | 424 |
10 | single-arm | 314 |
11 | multicentric | 297 |
12 | multi-site | 267 |
13 | three-arm | 252 |
14 | two-group | 208 |
15 | multi-institutional | 189 |
16 | noncomparative | 157 |
17 | two-armed | 125 |
18 | 2-arm | 124 |
19 | 3-arm | 108 |
20 | non-interventional | 105 |
21 | multicentered | 98 |
22 | single-institution | 93 |
23 | monocentric | 87 |
24 | three-armed | 83 |
25 | 2-group | 69 |
26 | four-arm | 67 |
27 | two-center | 65 |
28 | phase-iii | 63 |
29 | three-group | 60 |
30 | two-centre | 46 |
31 | multi-centered | 45 |
32 | single-group | 40 |
33 | 2-part | 39 |
34 | 4-arm | 37 |
35 | multi-centred | 36 |
36 | stepped-wedge | 33 |
37 | multi-national | 32 |
38 | multi-country | 31 |
39 | non-blind | 30 |
40 | 3-group | 28 |
41 | one-group | 28 |
42 | multicentred | 26 |
43 | phase-3 | 24 |
44 | community-randomized | 23 |
45 | two-county | 23 |
46 | 3-armed | 22 |
47 | monocenter | 21 |
48 | multi-centric | 20 |
49 | multicountry | 20 |
50 | multiinstitutional | 18 |
51 | parallel-designed | 17 |
52 | 2-armed | 16 |
53 | comparative-effectiveness | 14 |
54 | unicenter | 14 |
55 | multiclinic | 13 |
56 | multiple-center | 13 |
57 | single-institutional | 13 |
58 | five-arm | 12 |
59 | four-site | 12 |
60 | single-centred | 11 |
61 | single-surgeon | 11 |
62 | community-randomised | 10 |
63 | four-armed | 10 |
64 | single-centered | 10 |
65 | dual-center | 9 |
66 | multi-institution | 9 |
67 | two-cohort | 9 |
68 | 4-center | 8 |
69 | cao/aro/aio-94 | 8 |
70 | 50-week | 7 |
71 | binational | 7 |
72 | four-center | 7 |
73 | geparquinto | 7 |
74 | multisurgeon | 7 |
75 | three-centre | 7 |
76 | five-center | 6 |
77 | fully-powered | 6 |
78 | mono-center | 6 |
79 | multipractice | 6 |
80 | one-center | 6 |
81 | semirandomized | 6 |
82 | six-center | 6 |
83 | verapamil-trandolapril | 6 |
84 | 3-center | 5 |
85 | 300-bed | 5 |
86 | dual-arm | 5 |
87 | lesser-quality | 5 |
88 | multihospital | 5 |
89 | reference-controlled | 5 |
90 | 5-arm | 4 |
91 | cvrct | 4 |
92 | d1-d3 | 4 |
93 | double-centre | 4 |
94 | european-australian | 4 |
95 | five-site | 4 |
96 | geparquattro | 4 |
97 | gp-based | 4 |
98 | group-randomised | 4 |
99 | low-powered | 4 |
100 | mono-centre | 4 |
101 | multicenters | 4 |
102 | post-test-only | 4 |
103 | ptcl-restricted | 4 |
104 | sample-sized | 4 |
105 | self-addressed | 4 |
106 | twenty-year | 4 |
107 | 2-centre | 3 |
108 | 2010-patient | 3 |
109 | 51-week | 3 |
110 | certican | 3 |
111 | equinox | 3 |
112 | grader-blinded | 3 |
113 | mono-centric | 3 |
114 | multicohort | 3 |
115 | no-profit | 3 |
116 | novus | 3 |
117 | seven-arm | 3 |
118 | seven-center | 3 |
119 | seven-site | 3 |
120 | singlecenter | 3 |
121 | thrilling | 3 |
122 | time-sequence | 3 |
123 | 1,300-patient | 2 |
124 | 20-community | 2 |
125 | 3558 | 2 |
126 | 40-fr | 2 |
127 | 48-participant | 2 |
128 | 600-patient | 2 |
129 | 82b | 2 |
130 | 82c | 2 |
131 | 9-center | 2 |
132 | achieve-1 | 2 |
133 | beggarticks | 2 |
134 | calorie-sufficient | 2 |
135 | co-published | 2 |
136 | cohort-nested | 2 |
137 | community-planned | 2 |
138 | cyp2c9/10 | 2 |
139 | daily-level | 2 |
140 | descriptive-analytical | 2 |
141 | double-mask | 2 |
142 | ectaz | 2 |
143 | factorial-designed | 2 |
144 | household-cluster | 2 |
145 | identically-designed | 2 |
146 | kopac | 2 |
147 | limited-scope | 2 |
148 | locally-tailored | 2 |
149 | magrit | 2 |
150 | mhf-diet | 2 |
151 | microtechnology | 2 |
152 | multicampus | 2 |
153 | multiple-project | 2 |
154 | non-double-blind | 2 |
155 | non-ivf | 2 |
156 | non-thienopyridine | 2 |
157 | one-pill | 2 |
158 | phase-iiib | 2 |
159 | phosphatonin | 2 |
160 | pore-sized | 2 |
161 | post-only | 2 |
162 | replicate-use | 2 |
163 | resident-led | 2 |
164 | semi-isolated | 2 |
165 | semiblinded | 2 |
166 | sharp-pointed | 2 |
167 | single-assessor | 2 |
168 | six-armed | 2 |
169 | staggered-entry | 2 |
170 | statine | 2 |
171 | surgeon-blinded | 2 |
172 | te23 | 2 |
173 | trackball | 2 |
174 | triazolobenzodiazepine | 2 |
175 | trihexose | 2 |
176 | triventricular | 2 |
177 | two-arms | 2 |
178 | verapamil-sr/trandolapril | 2 |
179 | ,were | 1 |
180 | 0.75-ma | 1 |
181 | 0.9-ma | 1 |
182 | 1,300-bed | 1 |
183 | 1,5-benzodiazepine | 1 |
184 | 1.7-cm | 1 |
185 | 10-16-week | 1 |
186 | 104:12518-12523 | 1 |
187 | 11-nprs | 1 |
188 | 12-class | 1 |
189 | 15,760 | 1 |
190 | 15-lap | 1 |
191 | 1551-g | 1 |
192 | 16-24-week | 1 |
193 | 17-question | 1 |
194 | 19-center | 1 |
195 | 2,010-patient | 1 |
196 | 2-aminoazine | 1 |
197 | 2-benzyloxy- | 1 |
198 | 2-oxoaldehyde | 1 |
199 | 2-weeks-on | 1 |
200 | 2000-patient | 1 |
201 | 22-community | 1 |
202 | 25-institution | 1 |
203 | 29-month-period | 1 |
204 | 3-nitro- | 1 |
205 | 3-parallel-arm | 1 |
206 | 3-phased | 1 |
207 | 3.4-yr | 1 |
208 | 3000-patient | 1 |
209 | 31-bed | 1 |
210 | 31-patient | 1 |
211 | 3300-participant | 1 |
212 | 34-residue | 1 |
213 | 36-antenna | 1 |
214 | 383-d | 1 |
215 | 39-center | 1 |
216 | 390-bed | 1 |
217 | 4'-hydroxy-3-methoxyflavone | 1 |
218 | 4-lesson | 1 |
219 | 4-wave | 1 |
220 | 4-year-period | 1 |
221 | 4.25-year | 1 |
222 | 4000-patient | 1 |
223 | 42-night | 1 |
224 | 42.5-kda | 1 |
225 | 5-w | 1 |
226 | 5.0ml | 1 |
227 | 50j | 1 |
228 | 510k-approved | 1 |
229 | 6,711 | 1 |
230 | 6-12-week | 1 |
231 | 6-arm | 1 |
232 | 60-ma | 1 |
233 | 61-item | 1 |
234 | 7,447-participant | 1 |
235 | 7-center | 1 |
236 | 700-patient | 1 |
237 | 7000-patient | 1 |
238 | 75-base | 1 |
239 | 76-item | 1 |
240 | 78-day | 1 |
241 | 79-patient | 1 |
242 | 9-trial | 1 |
243 | 90-patient | 1 |
244 | 915-mhz | 1 |
245 | 95,299-bp-long | 1 |
246 | arteries-iv | 1 |
247 | association-9802 | 1 |
248 | australia.design | 1 |
249 | babygirl | 1 |
250 | balaclava | 1 |
251 | barriada | 1 |
252 | bayesian-framework | 1 |
253 | bee-derived | 1 |
254 | behaviorally-centered | 1 |
255 | bi-gene | 1 |
256 | bio-inactive | 1 |
257 | boggy | 1 |
258 | bookmark | 1 |
259 | booster-dose | 1 |
260 | botiquín | 1 |
261 | breathtron® | 1 |
262 | busybody | 1 |
263 | c-counter | 1 |
264 | c-free | 1 |
265 | c-galloylglycoside | 1 |
266 | c.584dela | 1 |
267 | calorie-reduced | 1 |
268 | cao-aro | 1 |
269 | carbohydrate-coated | 1 |
270 | caregiver-youth | 1 |
271 | carotenoid-controlled | 1 |
272 | cbt-naive | 1 |
273 | cd4-related | 1 |
274 | cdc-designated | 1 |
275 | chemically-activated | 1 |
276 | chloride-reduced | 1 |
277 | chondrodystrophy | 1 |
278 | chore/burden | 1 |
279 | cicatrizant | 1 |
280 | cilinical | 1 |
281 | cis-c | 1 |
282 | clarificant | 1 |
283 | clear-ivh | 1 |
284 | clinic-modelling | 1 |
285 | co-sensitizer | 1 |
286 | codicil | 1 |
287 | cofactor-based-inhibitor | 1 |
288 | cognin | 1 |
289 | community-integrated | 1 |
290 | comparative-group | 1 |
291 | conceptually-based | 1 |
292 | copa-airline | 1 |
293 | coping-technique | 1 |
294 | copper-sulfate-filled | 1 |
295 | cormet | 1 |
296 | corymb | 1 |
297 | counterproof | 1 |
298 | county-owned | 1 |
299 | cpo-based | 1 |
300 | crca | 1 |
301 | cut-and-carry | 1 |
302 | cycling-to-exhaustion | 1 |
303 | cyclooxygenase-inhibitor | 1 |
304 | cyclopentyltriazolopyrimidine | 1 |
305 | d2/d3-antagonist | 1 |
306 | danish-austrian | 1 |
307 | deep-reaching | 1 |
308 | defensive-like | 1 |
309 | defucosylated | 1 |
310 | dental-directed | 1 |
311 | denunciation | 1 |
312 | descriptive-analysis | 1 |
313 | dhhs-funded | 1 |
314 | dichotomousoutcome | 1 |
315 | dictionary-based | 1 |
316 | dielectrophile | 1 |
317 | difference.one | 1 |
318 | dimethylbiguanide | 1 |
319 | dinucleophile | 1 |
320 | diphenylbutylpiperidine | 1 |
321 | dissonance-enhancing | 1 |
322 | district-based | 1 |
323 | disulfide-deficient | 1 |
324 | dolderbar | 1 |
325 | dose-block-randomized | 1 |
326 | dose-searching | 1 |
327 | dose/duration-ranging | 1 |
328 | double-control | 1 |
329 | double-phased | 1 |
330 | double/blind | 1 |
331 | dutpase-like | 1 |
332 | dysnatraemia | 1 |
333 | fast-learning | 1 |
334 | fast-mapping | 1 |
335 | febuxostat/allopurinol | 1 |
336 | fiancée | 1 |
337 | firefighter-delivered | 1 |
338 | first-in-disease | 1 |
339 | five-centre | 1 |
340 | five-contact | 1 |
341 | five-subject | 1 |
342 | flavone-rich | 1 |
343 | flexstation | 1 |
344 | flower-specific | 1 |
345 | fluoro-chinolone | 1 |
346 | forsch | 1 |
347 | four-parallel-arm | 1 |
348 | four-trial | 1 |
349 | fourcenter | 1 |
350 | framework/theory | 1 |
351 | g-csf- | 1 |
352 | galactosyl-α | 1 |
353 | gamma-counter | 1 |
354 | gauguin | 1 |
355 | gene-of-interest | 1 |
356 | geneticist/oncologist | 1 |
357 | glutathione-independent | 1 |
358 | gold-shaded | 1 |
359 | goldilocks | 1 |
360 | gondwanatherian | 1 |
361 | growing-rod | 1 |
362 | haemocoel | 1 |
363 | half-solid | 1 |
364 | haloperidol-referenced | 1 |
365 | hawaiian-based | 1 |
366 | he65-like | 1 |
367 | head-mounted-display | 1 |
368 | health-literacy-sensitive | 1 |
369 | helmet-type | 1 |
370 | heparin-sensitive | 1 |
371 | hf-nurse | 1 |
372 | high-complex-carbohydrate | 1 |
373 | high-retention | 1 |
374 | high-risk-population | 1 |
375 | high-sense-of-control | 1 |
376 | high-wnt | 1 |
377 | hilbert-transform | 1 |
378 | hispanic-specific | 1 |
379 | hmg-coa-reductase-inhibitor | 1 |
380 | hodos | 1 |
381 | hr=1.14 | 1 |
382 | hummock | 1 |
383 | hunch | 1 |
384 | hyper-reflexive | 1 |
385 | hyperflexible | 1 |
386 | hypermigratory | 1 |
387 | intra-lock | 1 |
388 | jew | 1 |
389 | k-space-segmented | 1 |
390 | ketoaldehyde | 1 |
391 | lactose-negative | 1 |
392 | lard-based | 1 |
393 | large-gauge | 1 |
394 | large-numbered | 1 |
395 | later-acting | 1 |
396 | less-distinct | 1 |
397 | light-pecking | 1 |
398 | light-porous-particle | 1 |
399 | lighthearted | 1 |
400 | lipex-403 | 1 |
401 | llama-derived | 1 |
402 | logistic-regression-model | 1 |
403 | longport | 1 |
404 | low-impulsivity | 1 |
405 | low-phase | 1 |
406 | low-resource-demand | 1 |
407 | lym-3001 | 1 |
408 | m-inflated | 1 |
409 | maasol | 1 |
410 | magnesium-mediated | 1 |
411 | male-focused | 1 |
412 | mannose-rich | 1 |
413 | margit | 1 |
414 | matrixed | 1 |
415 | meatourethroscope | 1 |
416 | medication-withdrawal | 1 |
417 | medium-temperature | 1 |
418 | mek-inhibitor-sensitive | 1 |
419 | melibiose-negative | 1 |
420 | metallo-ß-lactamase | 1 |
421 | microbrewery | 1 |
422 | midewanniquay | 1 |
423 | mir-371 | 1 |
424 | mirtron | 1 |
425 | mmc/5-fu | 1 |
426 | monarchy | 1 |
427 | monomodality | 1 |
428 | month/bimonthly | 1 |
429 | multi-behavioral | 1 |
430 | multi-centre-randomised-trial | 1 |
431 | multi-intention | 1 |
432 | multi-interval | 1 |
433 | multi-night | 1 |
434 | multi-replicon | 1 |
435 | multicenter-cooperative | 1 |
436 | multicenter-randomized | 1 |
437 | multiphased | 1 |
438 | multiple-blind | 1 |
439 | multiprovince | 1 |
440 | myopia-control | 1 |
441 | naphthalene-derivative | 1 |
442 | nephrostomy-tube | 1 |
443 | net-cage | 1 |
444 | neurolinguist | 1 |
445 | nida-funded | 1 |
446 | nine-center | 1 |
447 | no-mix | 1 |
448 | non-amphetamine | 1 |
449 | non-betablocker | 1 |
450 | non-calorie-restricted | 1 |
451 | non-detachable | 1 |
452 | non-detubularised | 1 |
453 | non-isotropic | 1 |
454 | non-plasma-derived | 1 |
455 | non-protein-forming | 1 |
456 | non-rattlesnake | 1 |
457 | non-sequitur | 1 |
458 | noncentralized | 1 |
459 | noncollaborative | 1 |
460 | nonechocardiographer | 1 |
461 | noninferiority-designed | 1 |
462 | nonpelleted | 1 |
463 | nonphosphate | 1 |
464 | nonrandomized/partly | 1 |
465 | nonrestricted | 1 |
466 | north-to-south | 1 |
467 | nos-independent | 1 |
468 | nurse-presented | 1 |
469 | older-specific | 1 |
470 | orthopterans | 1 |
471 | p110δinhibitor | 1 |
472 | pan-world | 1 |
473 | parallel-group-design | 1 |
474 | participation-oriented | 1 |
475 | patient-selective | 1 |
476 | patient/employee/employer/physician | 1 |
477 | peridischarge | 1 |
478 | pharyngolaryngobronchitis | 1 |
479 | phosphatase-resistant | 1 |
480 | phosphatidylethnolamine | 1 |
481 | phosphatidylgylycerol | 1 |
482 | photo-novel | 1 |
483 | phthalocyanine-derivative | 1 |
484 | physician-blind | 1 |
485 | physician-sponsored | 1 |
486 | picture-analyzer | 1 |
487 | pidgley | 1 |
488 | placed-controlled | 1 |
489 | platelet-stimulating | 1 |
490 | plum-sized | 1 |
491 | polymercaptosiloxane | 1 |
492 | post-2005 | 1 |
493 | pqdt | 1 |
494 | pre-post-design | 1 |
495 | pre-switched | 1 |
496 | preevaluation | 1 |
497 | preperitioneal | 1 |
498 | pride- | 1 |
499 | progenitor-like | 1 |
500 | proteome-scale | 1 |
501 | proto-typical | 1 |
502 | pseudo-residual | 1 |
503 | pyranoquinolone | 1 |
504 | q318x | 1 |
505 | quasy-experimental | 1 |
506 | raisin- | 1 |
507 | random-coefficient-dependent | 1 |
508 | randomized-controlled-treatment | 1 |
509 | rectally-applied | 1 |
510 | relapsed-aml2001/01 | 1 |
511 | researcher-initiated | 1 |
512 | retrieval-phase | 1 |
513 | rickettsia-like | 1 |
514 | rotodynamic | 1 |
515 | round-bottomed | 1 |
516 | sam-riboswitch | 1 |
517 | science.finally | 1 |
518 | self-inducible | 1 |
519 | semi-woody | 1 |
520 | semielevated | 1 |
521 | seroprophylaxis | 1 |
522 | seventeen-centre | 1 |
523 | sewer/gutter | 1 |
524 | shifts-randomized | 1 |
525 | sibling-split | 1 |
526 | simple-blinded | 1 |
527 | simple-in-design | 1 |
528 | simple-operating | 1 |
529 | single-antibiotic | 1 |
530 | single-bind | 1 |
531 | single-headed-toothbrush | 1 |
532 | single-macronutrient | 1 |
533 | single-reviewer | 1 |
534 | single-tiered | 1 |
535 | single-turn | 1 |
536 | single/multicenter | 1 |
537 | sittingposition | 1 |
538 | six-sites | 1 |
539 | six-week-treatment | 1 |
540 | soap-opera-themed | 1 |
541 | solemn | 1 |
542 | sound-proofed | 1 |
543 | soy-protein-isolate | 1 |
544 | sp6likevirus | 1 |
545 | specialist-administered | 1 |
546 | sperm-interacting | 1 |
547 | staged-based | 1 |
548 | strain-unspecific | 1 |
549 | strawberry- | 1 |
550 | study-case-control | 1 |
551 | subcutaneous-mucosa | 1 |
552 | sulphonlyurea | 1 |
553 | superblade | 1 |
554 | surgeon-masked | 1 |
555 | task-battery | 1 |
556 | teammate | 1 |
557 | temporally-correct | 1 |
558 | temporary-type | 1 |
559 | ten-variable | 1 |
560 | tensipresser | 1 |
561 | test-age-equivalent | 1 |
562 | test-chart | 1 |
563 | tetrahexose | 1 |
564 | tetrahydrobenzocyclononenone | 1 |
565 | th1-pathway | 1 |
566 | then-standard | 1 |
567 | theoretically-defensible | 1 |
568 | theoreticallydriven | 1 |
569 | three-attack | 1 |
570 | three-plus-three | 1 |
571 | time-clustered | 1 |
572 | titration-protocol | 1 |
573 | tnfr1/jnk1/2 | 1 |
574 | toluene-resistant | 1 |
575 | training-independent | 1 |
576 | trans-national | 1 |
577 | treatment-derived | 1 |
578 | trial.obviously | 1 |
579 | triple-injection | 1 |
580 | trpv1-antagonist | 1 |
581 | tunnel-ventilated | 1 |
582 | twin-center | 1 |
583 | two-centred | 1 |
584 | two-chambered | 1 |
585 | two-diet | 1 |
586 | two-pole | 1 |
587 | two-treatment-arms | 1 |
588 | uichronic | 1 |
589 | ultrasonographic-screening | 1 |
590 | undoable | 1 |
591 | universal-coverage | 1 |
592 | university-affiliate | 1 |
593 | user-driven | 1 |
594 | vaccine-probe-study | 1 |
595 | varicocoele | 1 |
596 | viking | 1 |
597 | visually-identical | 1 |
598 | vulnery | 1 |
599 | wearisome | 1 |
600 | well-corticated | 1 |
601 | well-randomized | 1 |
602 | westerner | 1 |
603 | westlaw | 1 |
604 | wide-reach | 1 |
605 | widespread-growing | 1 |
606 | windbreak | 1 |
607 | within-nested | 1 |
608 | within-organizations | 1 |
609 | within-subject-design | 1 |
610 | woman.usually | 1 |
611 | yoghurt- | 1 |
612 | zinc-metalloendopeptidase | 1 |
613 | ø5-mm | 1 |
614 | κ³-manner | 1 |
615 | μ3-hydride | 1 |
616 | €590±43 | 1 |
617 | ≤68-week | 1 |
1 | ,were | 1 |
2 | 0.75-ma | 1 |
3 | 0.9-ma | 1 |
4 | 1,300-bed | 1 |
5 | 1,300-patient | 2 |
6 | 1,5-benzodiazepine | 1 |
7 | 1.7-cm | 1 |
8 | 10-16-week | 1 |
9 | 104:12518-12523 | 1 |
10 | 11-nprs | 1 |
11 | 12-class | 1 |
12 | 15,760 | 1 |
13 | 15-lap | 1 |
14 | 1551-g | 1 |
15 | 16-24-week | 1 |
16 | 17-question | 1 |
17 | 19-center | 1 |
18 | 2,010-patient | 1 |
19 | 2-aminoazine | 1 |
20 | 2-arm | 124 |
21 | 2-armed | 16 |
22 | 2-benzyloxy- | 1 |
23 | 2-centre | 3 |
24 | 2-group | 69 |
25 | 2-oxoaldehyde | 1 |
26 | 2-part | 39 |
27 | 2-weeks-on | 1 |
28 | 20-community | 2 |
29 | 2000-patient | 1 |
30 | 2010-patient | 3 |
31 | 22-community | 1 |
32 | 25-institution | 1 |
33 | 29-month-period | 1 |
34 | 3-arm | 108 |
35 | 3-armed | 22 |
36 | 3-center | 5 |
37 | 3-group | 28 |
38 | 3-nitro- | 1 |
39 | 3-parallel-arm | 1 |
40 | 3-phased | 1 |
41 | 3.4-yr | 1 |
42 | 300-bed | 5 |
43 | 3000-patient | 1 |
44 | 31-bed | 1 |
45 | 31-patient | 1 |
46 | 3300-participant | 1 |
47 | 34-residue | 1 |
48 | 3558 | 2 |
49 | 36-antenna | 1 |
50 | 383-d | 1 |
51 | 39-center | 1 |
52 | 390-bed | 1 |
53 | 4'-hydroxy-3-methoxyflavone | 1 |
54 | 4-arm | 37 |
55 | 4-center | 8 |
56 | 4-lesson | 1 |
57 | 4-wave | 1 |
58 | 4-year-period | 1 |
59 | 4.25-year | 1 |
60 | 40-fr | 2 |
61 | 4000-patient | 1 |
62 | 42-night | 1 |
63 | 42.5-kda | 1 |
64 | 48-participant | 2 |
65 | 5-arm | 4 |
66 | 5-w | 1 |
67 | 5.0ml | 1 |
68 | 50-week | 7 |
69 | 50j | 1 |
70 | 51-week | 3 |
71 | 510k-approved | 1 |
72 | 6,711 | 1 |
73 | 6-12-week | 1 |
74 | 6-arm | 1 |
75 | 60-ma | 1 |
76 | 600-patient | 2 |
77 | 61-item | 1 |
78 | 7,447-participant | 1 |
79 | 7-center | 1 |
80 | 700-patient | 1 |
81 | 7000-patient | 1 |
82 | 75-base | 1 |
83 | 76-item | 1 |
84 | 78-day | 1 |
85 | 79-patient | 1 |
86 | 82b | 2 |
87 | 82c | 2 |
88 | 9-center | 2 |
89 | 9-trial | 1 |
90 | 90-patient | 1 |
91 | 915-mhz | 1 |
92 | 95,299-bp-long | 1 |
93 | achieve-1 | 2 |
94 | arteries-iv | 1 |
95 | association-9802 | 1 |
96 | australia.design | 1 |
97 | babygirl | 1 |
98 | balaclava | 1 |
99 | barriada | 1 |
100 | bayesian-framework | 1 |
101 | bee-derived | 1 |
102 | beggarticks | 2 |
103 | behaviorally-centered | 1 |
104 | bi-gene | 1 |
105 | binational | 7 |
106 | bio-inactive | 1 |
107 | boggy | 1 |
108 | bookmark | 1 |
109 | booster-dose | 1 |
110 | botiquín | 1 |
111 | breathtron® | 1 |
112 | busybody | 1 |
113 | c-counter | 1 |
114 | c-free | 1 |
115 | c-galloylglycoside | 1 |
116 | c.584dela | 1 |
117 | calorie-reduced | 1 |
118 | calorie-sufficient | 2 |
119 | cao-aro | 1 |
120 | cao/aro/aio-94 | 8 |
121 | carbohydrate-coated | 1 |
122 | caregiver-youth | 1 |
123 | carotenoid-controlled | 1 |
124 | cbt-naive | 1 |
125 | cd4-related | 1 |
126 | cdc-designated | 1 |
127 | certican | 3 |
128 | chemically-activated | 1 |
129 | chloride-reduced | 1 |
130 | chondrodystrophy | 1 |
131 | chore/burden | 1 |
132 | cicatrizant | 1 |
133 | cilinical | 1 |
134 | cis-c | 1 |
135 | clarificant | 1 |
136 | clear-ivh | 1 |
137 | clinic-modelling | 1 |
138 | co-published | 2 |
139 | co-sensitizer | 1 |
140 | codicil | 1 |
141 | cofactor-based-inhibitor | 1 |
142 | cognin | 1 |
143 | cohort-nested | 2 |
144 | community-integrated | 1 |
145 | community-planned | 2 |
146 | community-randomised | 10 |
147 | community-randomized | 23 |
148 | comparative-effectiveness | 14 |
149 | comparative-group | 1 |
150 | conceptually-based | 1 |
151 | copa-airline | 1 |
152 | coping-technique | 1 |
153 | copper-sulfate-filled | 1 |
154 | cormet | 1 |
155 | corymb | 1 |
156 | counterproof | 1 |
157 | county-owned | 1 |
158 | cpo-based | 1 |
159 | crca | 1 |
160 | cut-and-carry | 1 |
161 | cvrct | 4 |
162 | cycling-to-exhaustion | 1 |
163 | cyclooxygenase-inhibitor | 1 |
164 | cyclopentyltriazolopyrimidine | 1 |
165 | cyp2c9/10 | 2 |
166 | d1-d3 | 4 |
167 | d2/d3-antagonist | 1 |
168 | daily-level | 2 |
169 | danish-austrian | 1 |
170 | deep-reaching | 1 |
171 | defensive-like | 1 |
172 | defucosylated | 1 |
173 | dental-directed | 1 |
174 | denunciation | 1 |
175 | descriptive-analysis | 1 |
176 | descriptive-analytical | 2 |
177 | dhhs-funded | 1 |
178 | dichotomousoutcome | 1 |
179 | dictionary-based | 1 |
180 | dielectrophile | 1 |
181 | difference.one | 1 |
182 | dimethylbiguanide | 1 |
183 | dinucleophile | 1 |
184 | diphenylbutylpiperidine | 1 |
185 | dissonance-enhancing | 1 |
186 | district-based | 1 |
187 | disulfide-deficient | 1 |
188 | dolderbar | 1 |
189 | dose-block-randomized | 1 |
190 | dose-searching | 1 |
191 | dose/duration-ranging | 1 |
192 | double-centre | 4 |
193 | double-control | 1 |
194 | double-mask | 2 |
195 | double-phased | 1 |
196 | double/blind | 1 |
197 | dual-arm | 5 |
198 | dual-center | 9 |
199 | dutpase-like | 1 |
200 | dysnatraemia | 1 |
201 | ectaz | 2 |
202 | equinox | 3 |
203 | european-australian | 4 |
204 | factorial-designed | 2 |
205 | fast-learning | 1 |
206 | fast-mapping | 1 |
207 | febuxostat/allopurinol | 1 |
208 | fiancée | 1 |
209 | firefighter-delivered | 1 |
210 | first-in-disease | 1 |
211 | five-arm | 12 |
212 | five-center | 6 |
213 | five-centre | 1 |
214 | five-contact | 1 |
215 | five-site | 4 |
216 | five-subject | 1 |
217 | flavone-rich | 1 |
218 | flexstation | 1 |
219 | flower-specific | 1 |
220 | fluoro-chinolone | 1 |
221 | forsch | 1 |
222 | four-arm | 67 |
223 | four-armed | 10 |
224 | four-center | 7 |
225 | four-parallel-arm | 1 |
226 | four-site | 12 |
227 | four-trial | 1 |
228 | fourcenter | 1 |
229 | framework/theory | 1 |
230 | fully-powered | 6 |
231 | g-csf- | 1 |
232 | galactosyl-α | 1 |
233 | gamma-counter | 1 |
234 | gauguin | 1 |
235 | gene-of-interest | 1 |
236 | geneticist/oncologist | 1 |
237 | geparquattro | 4 |
238 | geparquinto | 7 |
239 | glutathione-independent | 1 |
240 | gold-shaded | 1 |
241 | goldilocks | 1 |
242 | gondwanatherian | 1 |
243 | gp-based | 4 |
244 | grader-blinded | 3 |
245 | group-randomised | 4 |
246 | growing-rod | 1 |
247 | haemocoel | 1 |
248 | half-solid | 1 |
249 | haloperidol-referenced | 1 |
250 | hawaiian-based | 1 |
251 | he65-like | 1 |
252 | head-mounted-display | 1 |
253 | health-literacy-sensitive | 1 |
254 | helmet-type | 1 |
255 | heparin-sensitive | 1 |
256 | hf-nurse | 1 |
257 | high-complex-carbohydrate | 1 |
258 | high-retention | 1 |
259 | high-risk-population | 1 |
260 | high-sense-of-control | 1 |
261 | high-wnt | 1 |
262 | hilbert-transform | 1 |
263 | hispanic-specific | 1 |
264 | hmg-coa-reductase-inhibitor | 1 |
265 | hodos | 1 |
266 | household-cluster | 2 |
267 | hr=1.14 | 1 |
268 | hummock | 1 |
269 | hunch | 1 |
270 | hyper-reflexive | 1 |
271 | hyperflexible | 1 |
272 | hypermigratory | 1 |
273 | identically-designed | 2 |
274 | intra-lock | 1 |
275 | jew | 1 |
276 | k-space-segmented | 1 |
277 | ketoaldehyde | 1 |
278 | kopac | 2 |
279 | lactose-negative | 1 |
280 | lard-based | 1 |
281 | large-gauge | 1 |
282 | large-numbered | 1 |
283 | later-acting | 1 |
284 | less-distinct | 1 |
285 | lesser-quality | 5 |
286 | light-pecking | 1 |
287 | light-porous-particle | 1 |
288 | lighthearted | 1 |
289 | limited-scope | 2 |
290 | lipex-403 | 1 |
291 | llama-derived | 1 |
292 | locally-tailored | 2 |
293 | logistic-regression-model | 1 |
294 | longport | 1 |
295 | low-impulsivity | 1 |
296 | low-phase | 1 |
297 | low-powered | 4 |
298 | low-resource-demand | 1 |
299 | lym-3001 | 1 |
300 | m-inflated | 1 |
301 | maasol | 1 |
302 | magnesium-mediated | 1 |
303 | magrit | 2 |
304 | male-focused | 1 |
305 | mannose-rich | 1 |
306 | margit | 1 |
307 | matrixed | 1 |
308 | meatourethroscope | 1 |
309 | medication-withdrawal | 1 |
310 | medium-temperature | 1 |
311 | mek-inhibitor-sensitive | 1 |
312 | melibiose-negative | 1 |
313 | metallo-ß-lactamase | 1 |
314 | mhf-diet | 2 |
315 | microbrewery | 1 |
316 | microtechnology | 2 |
317 | midewanniquay | 1 |
318 | mir-371 | 1 |
319 | mirtron | 1 |
320 | mmc/5-fu | 1 |
321 | monarchy | 1 |
322 | mono-center | 6 |
323 | mono-centre | 4 |
324 | mono-centric | 3 |
325 | monocenter | 21 |
326 | monocentric | 87 |
327 | monomodality | 1 |
328 | month/bimonthly | 1 |
329 | multi-behavioral | 1 |
330 | multi-center | 761 |
331 | multi-centered | 45 |
332 | multi-centre | 746 |
333 | multi-centre-randomised-trial | 1 |
334 | multi-centred | 36 |
335 | multi-centric | 20 |
336 | multi-country | 31 |
337 | multi-institution | 9 |
338 | multi-institutional | 189 |
339 | multi-intention | 1 |
340 | multi-interval | 1 |
341 | multi-national | 32 |
342 | multi-night | 1 |
343 | multi-replicon | 1 |
344 | multi-site | 267 |
345 | multicampus | 2 |
346 | multicenter | 9,074 |
347 | multicenter-cooperative | 1 |
348 | multicenter-randomized | 1 |
349 | multicentered | 98 |
350 | multicenters | 4 |
351 | multicentre | 3,200 |
352 | multicentred | 26 |
353 | multicentric | 297 |
354 | multiclinic | 13 |
355 | multicohort | 3 |
356 | multicountry | 20 |
357 | multihospital | 5 |
358 | multiinstitutional | 18 |
359 | multinational | 700 |
360 | multiphased | 1 |
361 | multiple-blind | 1 |
362 | multiple-center | 13 |
363 | multiple-project | 2 |
364 | multipractice | 6 |
365 | multiprovince | 1 |
366 | multisite | 553 |
367 | multisurgeon | 7 |
368 | myopia-control | 1 |
369 | naphthalene-derivative | 1 |
370 | nephrostomy-tube | 1 |
371 | net-cage | 1 |
372 | neurolinguist | 1 |
373 | nida-funded | 1 |
374 | nine-center | 1 |
375 | no-mix | 1 |
376 | no-profit | 3 |
377 | non-amphetamine | 1 |
378 | non-betablocker | 1 |
379 | non-blind | 30 |
380 | non-calorie-restricted | 1 |
381 | non-detachable | 1 |
382 | non-detubularised | 1 |
383 | non-double-blind | 2 |
384 | non-interventional | 105 |
385 | non-isotropic | 1 |
386 | non-ivf | 2 |
387 | non-plasma-derived | 1 |
388 | non-protein-forming | 1 |
389 | non-rattlesnake | 1 |
390 | non-sequitur | 1 |
391 | non-thienopyridine | 2 |
392 | noncentralized | 1 |
393 | noncollaborative | 1 |
394 | noncomparative | 157 |
395 | nonechocardiographer | 1 |
396 | noninferiority-designed | 1 |
397 | nonpelleted | 1 |
398 | nonphosphate | 1 |
399 | nonrandomized/partly | 1 |
400 | nonrestricted | 1 |
401 | north-to-south | 1 |
402 | nos-independent | 1 |
403 | novus | 3 |
404 | nurse-presented | 1 |
405 | older-specific | 1 |
406 | one-center | 6 |
407 | one-group | 28 |
408 | one-pill | 2 |
409 | orthopterans | 1 |
410 | p110δinhibitor | 1 |
411 | pan-world | 1 |
412 | parallel-designed | 17 |
413 | parallel-group-design | 1 |
414 | participation-oriented | 1 |
415 | patient-selective | 1 |
416 | patient/employee/employer/physician | 1 |
417 | peridischarge | 1 |
418 | pharyngolaryngobronchitis | 1 |
419 | phase-3 | 24 |
420 | phase-iii | 63 |
421 | phase-iiib | 2 |
422 | phosphatase-resistant | 1 |
423 | phosphatidylethnolamine | 1 |
424 | phosphatidylgylycerol | 1 |
425 | phosphatonin | 2 |
426 | photo-novel | 1 |
427 | phthalocyanine-derivative | 1 |
428 | physician-blind | 1 |
429 | physician-sponsored | 1 |
430 | picture-analyzer | 1 |
431 | pidgley | 1 |
432 | placed-controlled | 1 |
433 | platelet-stimulating | 1 |
434 | plum-sized | 1 |
435 | polymercaptosiloxane | 1 |
436 | pore-sized | 2 |
437 | post-2005 | 1 |
438 | post-only | 2 |
439 | post-test-only | 4 |
440 | pqdt | 1 |
441 | pre-post-design | 1 |
442 | pre-switched | 1 |
443 | preevaluation | 1 |
444 | preperitioneal | 1 |
445 | pride- | 1 |
446 | progenitor-like | 1 |
447 | proteome-scale | 1 |
448 | proto-typical | 1 |
449 | pseudo-residual | 1 |
450 | ptcl-restricted | 4 |
451 | pyranoquinolone | 1 |
452 | q318x | 1 |
453 | quasy-experimental | 1 |
454 | raisin- | 1 |
455 | random-coefficient-dependent | 1 |
456 | randomized-controlled-treatment | 1 |
457 | rectally-applied | 1 |
458 | reference-controlled | 5 |
459 | relapsed-aml2001/01 | 1 |
460 | replicate-use | 2 |
461 | researcher-initiated | 1 |
462 | resident-led | 2 |
463 | retrieval-phase | 1 |
464 | rickettsia-like | 1 |
465 | rotodynamic | 1 |
466 | round-bottomed | 1 |
467 | sam-riboswitch | 1 |
468 | sample-sized | 4 |
469 | science.finally | 1 |
470 | self-addressed | 4 |
471 | self-inducible | 1 |
472 | semi-isolated | 2 |
473 | semi-woody | 1 |
474 | semiblinded | 2 |
475 | semielevated | 1 |
476 | semirandomized | 6 |
477 | seroprophylaxis | 1 |
478 | seven-arm | 3 |
479 | seven-center | 3 |
480 | seven-site | 3 |
481 | seventeen-centre | 1 |
482 | sewer/gutter | 1 |
483 | sharp-pointed | 2 |
484 | shifts-randomized | 1 |
485 | sibling-split | 1 |
486 | simple-blinded | 1 |
487 | simple-in-design | 1 |
488 | simple-operating | 1 |
489 | single-antibiotic | 1 |
490 | single-arm | 314 |
491 | single-assessor | 2 |
492 | single-bind | 1 |
493 | single-center | 1,404 |
494 | single-centered | 10 |
495 | single-centre | 455 |
496 | single-centred | 11 |
497 | single-group | 40 |
498 | single-headed-toothbrush | 1 |
499 | single-institution | 93 |
500 | single-institutional | 13 |
501 | single-macronutrient | 1 |
502 | single-reviewer | 1 |
503 | single-surgeon | 11 |
504 | single-tiered | 1 |
505 | single-turn | 1 |
506 | single/multicenter | 1 |
507 | singlecenter | 3 |
508 | sittingposition | 1 |
509 | six-armed | 2 |
510 | six-center | 6 |
511 | six-sites | 1 |
512 | six-week-treatment | 1 |
513 | soap-opera-themed | 1 |
514 | solemn | 1 |
515 | sound-proofed | 1 |
516 | soy-protein-isolate | 1 |
517 | sp6likevirus | 1 |
518 | specialist-administered | 1 |
519 | sperm-interacting | 1 |
520 | staged-based | 1 |
521 | staggered-entry | 2 |
522 | statine | 2 |
523 | stepped-wedge | 33 |
524 | strain-unspecific | 1 |
525 | strawberry- | 1 |
526 | study-case-control | 1 |
527 | subcutaneous-mucosa | 1 |
528 | sulphonlyurea | 1 |
529 | superblade | 1 |
530 | surgeon-blinded | 2 |
531 | surgeon-masked | 1 |
532 | task-battery | 1 |
533 | te23 | 2 |
534 | teammate | 1 |
535 | temporally-correct | 1 |
536 | temporary-type | 1 |
537 | ten-variable | 1 |
538 | tensipresser | 1 |
539 | test-age-equivalent | 1 |
540 | test-chart | 1 |
541 | tetrahexose | 1 |
542 | tetrahydrobenzocyclononenone | 1 |
543 | th1-pathway | 1 |
544 | then-standard | 1 |
545 | theoretically-defensible | 1 |
546 | theoreticallydriven | 1 |
547 | three-arm | 252 |
548 | three-armed | 83 |
549 | three-attack | 1 |
550 | three-centre | 7 |
551 | three-group | 60 |
552 | three-plus-three | 1 |
553 | thrilling | 3 |
554 | time-clustered | 1 |
555 | time-sequence | 3 |
556 | titration-protocol | 1 |
557 | tnfr1/jnk1/2 | 1 |
558 | toluene-resistant | 1 |
559 | trackball | 2 |
560 | training-independent | 1 |
561 | trans-national | 1 |
562 | treatment-derived | 1 |
563 | trial.obviously | 1 |
564 | triazolobenzodiazepine | 2 |
565 | trihexose | 2 |
566 | triple-injection | 1 |
567 | triventricular | 2 |
568 | trpv1-antagonist | 1 |
569 | tunnel-ventilated | 1 |
570 | twenty-year | 4 |
571 | twin-center | 1 |
572 | two-arm | 424 |
573 | two-armed | 125 |
574 | two-arms | 2 |
575 | two-center | 65 |
576 | two-centre | 46 |
577 | two-centred | 1 |
578 | two-chambered | 1 |
579 | two-cohort | 9 |
580 | two-county | 23 |
581 | two-diet | 1 |
582 | two-group | 208 |
583 | two-pole | 1 |
584 | two-treatment-arms | 1 |
585 | uichronic | 1 |
586 | ultrasonographic-screening | 1 |
587 | undoable | 1 |
588 | unicenter | 14 |
589 | universal-coverage | 1 |
590 | university-affiliate | 1 |
591 | user-driven | 1 |
592 | vaccine-probe-study | 1 |
593 | varicocoele | 1 |
594 | verapamil-sr/trandolapril | 2 |
595 | verapamil-trandolapril | 6 |
596 | viking | 1 |
597 | visually-identical | 1 |
598 | vulnery | 1 |
599 | wearisome | 1 |
600 | well-corticated | 1 |
601 | well-randomized | 1 |
602 | westerner | 1 |
603 | westlaw | 1 |
604 | wide-reach | 1 |
605 | widespread-growing | 1 |
606 | windbreak | 1 |
607 | within-nested | 1 |
608 | within-organizations | 1 |
609 | within-subject-design | 1 |
610 | woman.usually | 1 |
611 | yoghurt- | 1 |
612 | zinc-metalloendopeptidase | 1 |
613 | ø5-mm | 1 |
614 | κ³-manner | 1 |
615 | μ3-hydride | 1 |
616 | €590±43 | 1 |
617 | ≤68-week | 1 |
1 | pride- | 1 |
2 | g-csf- | 1 |
3 | raisin- | 1 |
4 | 3-nitro- | 1 |
5 | yoghurt- | 1 |
6 | strawberry- | 1 |
7 | 2-benzyloxy- | 1 |
8 | cyp2c9/10 | 2 |
9 | 15,760 | 1 |
10 | achieve-1 | 2 |
11 | relapsed-aml2001/01 | 1 |
12 | lym-3001 | 1 |
13 | 6,711 | 1 |
14 | mir-371 | 1 |
15 | tnfr1/jnk1/2 | 1 |
16 | association-9802 | 1 |
17 | phase-3 | 24 |
18 | lipex-403 | 1 |
19 | 104:12518-12523 | 1 |
20 | te23 | 2 |
21 | €590±43 | 1 |
22 | d1-d3 | 4 |
23 | hr=1.14 | 1 |
24 | cao/aro/aio-94 | 8 |
25 | post-2005 | 1 |
26 | 3558 | 2 |
27 | crca | 1 |
28 | barriada | 1 |
29 | 42.5-kda | 1 |
30 | sulphonlyurea | 1 |
31 | dysnatraemia | 1 |
32 | c.584dela | 1 |
33 | 60-ma | 1 |
34 | 0.75-ma | 1 |
35 | 0.9-ma | 1 |
36 | 36-antenna | 1 |
37 | subcutaneous-mucosa | 1 |
38 | balaclava | 1 |
39 | 82b | 2 |
40 | phase-iiib | 2 |
41 | corymb | 1 |
42 | cis-c | 1 |
43 | 82c | 2 |
44 | kopac | 2 |
45 | hispanic-specific | 1 |
46 | older-specific | 1 |
47 | flower-specific | 1 |
48 | strain-unspecific | 1 |
49 | rotodynamic | 1 |
50 | multiclinic | 13 |
51 | uichronic | 1 |
52 | non-isotropic | 1 |
53 | multi-centric | 20 |
54 | mono-centric | 3 |
55 | multicentric | 297 |
56 | monocentric | 87 |
57 | single-antibiotic | 1 |
58 | 383-d | 1 |
59 | 300-bed | 5 |
60 | 1,300-bed | 1 |
61 | 390-bed | 1 |
62 | 31-bed | 1 |
63 | haloperidol-referenced | 1 |
64 | chloride-reduced | 1 |
65 | calorie-reduced | 1 |
66 | gold-shaded | 1 |
67 | simple-blinded | 1 |
68 | surgeon-blinded | 2 |
69 | grader-blinded | 3 |
70 | semiblinded | 2 |
71 | nida-funded | 1 |
72 | dhhs-funded | 1 |
73 | sound-proofed | 1 |
74 | pre-switched | 1 |
75 | co-published | 2 |
76 | rectally-applied | 1 |
77 | surgeon-masked | 1 |
78 | resident-led | 2 |
79 | copper-sulfate-filled | 1 |
80 | placed-controlled | 1 |
81 | carotenoid-controlled | 1 |
82 | reference-controlled | 5 |
83 | soap-opera-themed | 1 |
84 | round-bottomed | 1 |
85 | 2-armed | 16 |
86 | 3-armed | 22 |
87 | three-armed | 83 |
88 | two-armed | 125 |
89 | four-armed | 10 |
90 | six-armed | 2 |
91 | factorial-designed | 2 |
92 | parallel-designed | 17 |
93 | identically-designed | 2 |
94 | noninferiority-designed | 1 |
95 | community-planned | 2 |
96 | county-owned | 1 |
97 | two-chambered | 1 |
98 | large-numbered | 1 |
99 | single-tiered | 1 |
100 | single-centered | 10 |
101 | multi-centered | 45 |
102 | behaviorally-centered | 1 |
103 | multicentered | 98 |
104 | specialist-administered | 1 |
105 | time-clustered | 1 |
106 | firefighter-delivered | 1 |
107 | low-powered | 4 |
108 | fully-powered | 6 |
109 | locally-tailored | 2 |
110 | physician-sponsored | 1 |
111 | single-centred | 11 |
112 | multi-centred | 36 |
113 | two-centred | 1 |
114 | multicentred | 26 |
115 | staged-based | 1 |
116 | lard-based | 1 |
117 | hawaiian-based | 1 |
118 | cpo-based | 1 |
119 | gp-based | 4 |
120 | district-based | 1 |
121 | conceptually-based | 1 |
122 | dictionary-based | 1 |
123 | 3-phased | 1 |
124 | double-phased | 1 |
125 | multiphased | 1 |
126 | group-randomised | 4 |
127 | community-randomised | 10 |
128 | non-detubularised | 1 |
129 | self-addressed | 4 |
130 | male-focused | 1 |
131 | well-corticated | 1 |
132 | magnesium-mediated | 1 |
133 | researcher-initiated | 1 |
134 | cd4-related | 1 |
135 | m-inflated | 1 |
136 | tunnel-ventilated | 1 |
137 | semi-isolated | 2 |
138 | defucosylated | 1 |
139 | cdc-designated | 1 |
140 | carbohydrate-coated | 1 |
141 | community-integrated | 1 |
142 | semielevated | 1 |
143 | chemically-activated | 1 |
144 | dental-directed | 1 |
145 | non-calorie-restricted | 1 |
146 | ptcl-restricted | 4 |
147 | nonrestricted | 1 |
148 | nonpelleted | 1 |
149 | participation-oriented | 1 |
150 | k-space-segmented | 1 |
151 | nurse-presented | 1 |
152 | sharp-pointed | 2 |
153 | lighthearted | 1 |
154 | within-nested | 1 |
155 | cohort-nested | 2 |
156 | llama-derived | 1 |
157 | non-plasma-derived | 1 |
158 | bee-derived | 1 |
159 | treatment-derived | 1 |
160 | 510k-approved | 1 |
161 | matrixed | 1 |
162 | noncentralized | 1 |
163 | dose-block-randomized | 1 |
164 | well-randomized | 1 |
165 | multicenter-randomized | 1 |
166 | shifts-randomized | 1 |
167 | community-randomized | 23 |
168 | semirandomized | 6 |
169 | sample-sized | 4 |
170 | pore-sized | 2 |
171 | plum-sized | 1 |
172 | half-solid | 1 |
173 | pan-world | 1 |
174 | low-resource-demand | 1 |
175 | single-bind | 1 |
176 | non-double-blind | 2 |
177 | multiple-blind | 1 |
178 | physician-blind | 1 |
179 | non-blind | 30 |
180 | double/blind | 1 |
181 | 29-month-period | 1 |
182 | 4-year-period | 1 |
183 | growing-rod | 1 |
184 | then-standard | 1 |
185 | nephrostomy-tube | 1 |
186 | multipractice | 6 |
187 | time-sequence | 3 |
188 | multiprovince | 1 |
189 | superblade | 1 |
190 | dimethylbiguanide | 1 |
191 | μ3-hydride | 1 |
192 | c-galloylglycoside | 1 |
193 | ketoaldehyde | 1 |
194 | 2-oxoaldehyde | 1 |
195 | c-free | 1 |
196 | three-plus-three | 1 |
197 | net-cage | 1 |
198 | universal-coverage | 1 |
199 | stepped-wedge | 33 |
200 | peridischarge | 1 |
201 | large-gauge | 1 |
202 | non-rattlesnake | 1 |
203 | he65-like | 1 |
204 | rickettsia-like | 1 |
205 | dutpase-like | 1 |
206 | defensive-like | 1 |
207 | progenitor-like | 1 |
208 | proteome-scale | 1 |
209 | non-detachable | 1 |
210 | ten-variable | 1 |
211 | undoable | 1 |
212 | self-inducible | 1 |
213 | theoretically-defensible | 1 |
214 | hyperflexible | 1 |
215 | light-porous-particle | 1 |
216 | varicocoele | 1 |
217 | dinucleophile | 1 |
218 | dielectrophile | 1 |
219 | two-pole | 1 |
220 | dichotomousoutcome | 1 |
221 | wearisome | 1 |
222 | polymercaptosiloxane | 1 |
223 | bi-gene | 1 |
224 | cyclopentyltriazolopyrimidine | 1 |
225 | diphenylbutylpiperidine | 1 |
226 | non-thienopyridine | 2 |
227 | copa-airline | 1 |
228 | phosphatidylethnolamine | 1 |
229 | non-amphetamine | 1 |
230 | 1,5-benzodiazepine | 1 |
231 | triazolobenzodiazepine | 2 |
232 | statine | 2 |
233 | 2-aminoazine | 1 |
234 | difference.one | 1 |
235 | fluoro-chinolone | 1 |
236 | pyranoquinolone | 1 |
237 | tetrahydrobenzocyclononenone | 1 |
238 | 4'-hydroxy-3-methoxyflavone | 1 |
239 | limited-scope | 2 |
240 | meatourethroscope | 1 |
241 | helmet-type | 1 |
242 | temporary-type | 1 |
243 | ,were | 1 |
244 | 2-centre | 3 |
245 | three-centre | 7 |
246 | double-centre | 4 |
247 | single-centre | 455 |
248 | five-centre | 1 |
249 | multi-centre | 746 |
250 | seventeen-centre | 1 |
251 | mono-centre | 4 |
252 | two-centre | 46 |
253 | multicentre | 3,200 |
254 | medium-temperature | 1 |
255 | 75-base | 1 |
256 | zinc-metalloendopeptidase | 1 |
257 | first-in-disease | 1 |
258 | retrieval-phase | 1 |
259 | low-phase | 1 |
260 | metallo-ß-lactamase | 1 |
261 | booster-dose | 1 |
262 | tetrahexose | 1 |
263 | trihexose | 2 |
264 | hf-nurse | 1 |
265 | replicate-use | 2 |
266 | nonphosphate | 1 |
267 | university-affiliate | 1 |
268 | soy-protein-isolate | 1 |
269 | teammate | 1 |
270 | high-complex-carbohydrate | 1 |
271 | five-site | 4 |
272 | multi-site | 267 |
273 | seven-site | 3 |
274 | four-site | 12 |
275 | multisite | 553 |
276 | 34-residue | 1 |
277 | coping-technique | 1 |
278 | 4-wave | 1 |
279 | cbt-naive | 1 |
280 | melibiose-negative | 1 |
281 | lactose-negative | 1 |
282 | noncomparative | 157 |
283 | multicenter-cooperative | 1 |
284 | noncollaborative | 1 |
285 | naphthalene-derivative | 1 |
286 | phthalocyanine-derivative | 1 |
287 | bio-inactive | 1 |
288 | patient-selective | 1 |
289 | heparin-sensitive | 1 |
290 | mek-inhibitor-sensitive | 1 |
291 | health-literacy-sensitive | 1 |
292 | hyper-reflexive | 1 |
293 | fiancée | 1 |
294 | counterproof | 1 |
295 | non-ivf | 2 |
296 | 1551-g | 1 |
297 | dissonance-enhancing | 1 |
298 | dose/duration-ranging | 1 |
299 | deep-reaching | 1 |
300 | dose-searching | 1 |
301 | light-pecking | 1 |
302 | viking | 1 |
303 | clinic-modelling | 1 |
304 | thrilling | 3 |
305 | non-protein-forming | 1 |
306 | ultrasonographic-screening | 1 |
307 | fast-learning | 1 |
308 | fast-mapping | 1 |
309 | platelet-stimulating | 1 |
310 | simple-operating | 1 |
311 | later-acting | 1 |
312 | sperm-interacting | 1 |
313 | widespread-growing | 1 |
314 | 95,299-bp-long | 1 |
315 | wide-reach | 1 |
316 | flavone-rich | 1 |
317 | mannose-rich | 1 |
318 | hunch | 1 |
319 | forsch | 1 |
320 | sam-riboswitch | 1 |
321 | single-headed-toothbrush | 1 |
322 | north-to-south | 1 |
323 | caregiver-youth | 1 |
324 | clear-ivh | 1 |
325 | phase-iii | 63 |
326 | 50j | 1 |
327 | windbreak | 1 |
328 | three-attack | 1 |
329 | intra-lock | 1 |
330 | hummock | 1 |
331 | 50-week | 7 |
332 | 51-week | 3 |
333 | 6-12-week | 1 |
334 | 16-24-week | 1 |
335 | 10-16-week | 1 |
336 | ≤68-week | 1 |
337 | bookmark | 1 |
338 | bayesian-framework | 1 |
339 | double-mask | 2 |
340 | cilinical | 1 |
341 | proto-typical | 1 |
342 | visually-identical | 1 |
343 | descriptive-analytical | 2 |
344 | preperitioneal | 1 |
345 | 9-trial | 1 |
346 | multi-centre-randomised-trial | 1 |
347 | four-trial | 1 |
348 | multi-national | 32 |
349 | trans-national | 1 |
350 | binational | 7 |
351 | multinational | 700 |
352 | non-interventional | 105 |
353 | single-institutional | 13 |
354 | multi-institutional | 189 |
355 | multiinstitutional | 18 |
356 | multi-behavioral | 1 |
357 | multihospital | 5 |
358 | quasy-experimental | 1 |
359 | pseudo-residual | 1 |
360 | multi-interval | 1 |
361 | medication-withdrawal | 1 |
362 | logistic-regression-model | 1 |
363 | haemocoel | 1 |
364 | daily-level | 2 |
365 | photo-novel | 1 |
366 | codicil | 1 |
367 | verapamil-trandolapril | 6 |
368 | verapamil-sr/trandolapril | 2 |
369 | trackball | 2 |
370 | one-pill | 2 |
371 | 5.0ml | 1 |
372 | titration-protocol | 1 |
373 | febuxostat/allopurinol | 1 |
374 | phosphatidylgylycerol | 1 |
375 | myopia-control | 1 |
376 | double-control | 1 |
377 | study-case-control | 1 |
378 | high-sense-of-control | 1 |
379 | maasol | 1 |
380 | babygirl | 1 |
381 | 1.7-cm | 1 |
382 | 61-item | 1 |
383 | 76-item | 1 |
384 | ø5-mm | 1 |
385 | 2-arm | 124 |
386 | 3-arm | 108 |
387 | 4-arm | 37 |
388 | 5-arm | 4 |
389 | 6-arm | 1 |
390 | three-arm | 252 |
391 | single-arm | 314 |
392 | five-arm | 12 |
393 | dual-arm | 5 |
394 | 3-parallel-arm | 1 |
395 | four-parallel-arm | 1 |
396 | seven-arm | 3 |
397 | two-arm | 424 |
398 | four-arm | 67 |
399 | hilbert-transform | 1 |
400 | certican | 3 |
401 | patient/employee/employer/physician | 1 |
402 | european-australian | 4 |
403 | gondwanatherian | 1 |
404 | danish-austrian | 1 |
405 | chore/burden | 1 |
406 | user-driven | 1 |
407 | theoreticallydriven | 1 |
408 | simple-in-design | 1 |
409 | parallel-group-design | 1 |
410 | within-subject-design | 1 |
411 | pre-post-design | 1 |
412 | australia.design | 1 |
413 | cognin | 1 |
414 | phosphatonin | 2 |
415 | gauguin | 1 |
416 | solemn | 1 |
417 | 2-weeks-on | 1 |
418 | multi-replicon | 1 |
419 | single-surgeon | 11 |
420 | multisurgeon | 7 |
421 | denunciation | 1 |
422 | high-risk-population | 1 |
423 | flexstation | 1 |
424 | preevaluation | 1 |
425 | triple-injection | 1 |
426 | sittingposition | 1 |
427 | high-retention | 1 |
428 | multi-intention | 1 |
429 | 17-question | 1 |
430 | cycling-to-exhaustion | 1 |
431 | 25-institution | 1 |
432 | single-institution | 93 |
433 | multi-institution | 9 |
434 | mirtron | 1 |
435 | 4-lesson | 1 |
436 | single-turn | 1 |
437 | botiquín | 1 |
438 | cao-aro | 1 |
439 | geparquattro | 4 |
440 | geparquinto | 7 |
441 | 15-lap | 1 |
442 | 2-group | 69 |
443 | 3-group | 28 |
444 | three-group | 60 |
445 | single-group | 40 |
446 | one-group | 28 |
447 | comparative-group | 1 |
448 | two-group | 208 |
449 | dolderbar | 1 |
450 | 4.25-year | 1 |
451 | twenty-year | 4 |
452 | triventricular | 2 |
453 | nonechocardiographer | 1 |
454 | non-betablocker | 1 |
455 | κ³-manner | 1 |
456 | westerner | 1 |
457 | tensipresser | 1 |
458 | 3-center | 5 |
459 | 4-center | 8 |
460 | 7-center | 1 |
461 | 9-center | 2 |
462 | 19-center | 1 |
463 | 39-center | 1 |
464 | single-center | 1,404 |
465 | multiple-center | 13 |
466 | nine-center | 1 |
467 | one-center | 6 |
468 | five-center | 6 |
469 | multi-center | 761 |
470 | dual-center | 9 |
471 | seven-center | 3 |
472 | twin-center | 1 |
473 | mono-center | 6 |
474 | two-center | 65 |
475 | four-center | 7 |
476 | six-center | 6 |
477 | singlecenter | 3 |
478 | unicenter | 14 |
479 | multicenter | 9,074 |
480 | single/multicenter | 1 |
481 | monocenter | 21 |
482 | fourcenter | 1 |
483 | gamma-counter | 1 |
484 | c-counter | 1 |
485 | household-cluster | 2 |
486 | sewer/gutter | 1 |
487 | single-reviewer | 1 |
488 | co-sensitizer | 1 |
489 | picture-analyzer | 1 |
490 | 40-fr | 2 |
491 | single-assessor | 2 |
492 | cofactor-based-inhibitor | 1 |
493 | cyclooxygenase-inhibitor | 1 |
494 | hmg-coa-reductase-inhibitor | 1 |
495 | p110δinhibitor | 1 |
496 | non-sequitur | 1 |
497 | 3.4-yr | 1 |
498 | six-sites | 1 |
499 | descriptive-analysis | 1 |
500 | pharyngolaryngobronchitis | 1 |
501 | seroprophylaxis | 1 |
502 | beggarticks | 2 |
503 | goldilocks | 1 |
504 | two-arms | 2 |
505 | two-treatment-arms | 1 |
506 | orthopterans | 1 |
507 | within-organizations | 1 |
508 | hodos | 1 |
509 | multicenters | 4 |
510 | 11-nprs | 1 |
511 | 12-class | 1 |
512 | comparative-effectiveness | 14 |
513 | multicampus | 2 |
514 | sp6likevirus | 1 |
515 | novus | 3 |
516 | five-contact | 1 |
517 | five-subject | 1 |
518 | multiple-project | 2 |
519 | temporally-correct | 1 |
520 | less-distinct | 1 |
521 | cvrct | 4 |
522 | pqdt | 1 |
523 | mhf-diet | 2 |
524 | two-diet | 1 |
525 | cormet | 1 |
526 | 42-night | 1 |
527 | multi-night | 1 |
528 | no-profit | 3 |
529 | margit | 1 |
530 | sibling-split | 1 |
531 | magrit | 2 |
532 | clarificant | 1 |
533 | 3300-participant | 1 |
534 | 7,447-participant | 1 |
535 | 48-participant | 2 |
536 | toluene-resistant | 1 |
537 | phosphatase-resistant | 1 |
538 | cicatrizant | 1 |
539 | random-coefficient-dependent | 1 |
540 | glutathione-independent | 1 |
541 | training-independent | 1 |
542 | nos-independent | 1 |
543 | disulfide-deficient | 1 |
544 | calorie-sufficient | 2 |
545 | single-macronutrient | 1 |
546 | 2000-patient | 1 |
547 | 3000-patient | 1 |
548 | 4000-patient | 1 |
549 | 7000-patient | 1 |
550 | 1,300-patient | 2 |
551 | 600-patient | 2 |
552 | 700-patient | 1 |
553 | 2,010-patient | 1 |
554 | 2010-patient | 3 |
555 | 90-patient | 1 |
556 | 31-patient | 1 |
557 | 79-patient | 1 |
558 | test-age-equivalent | 1 |
559 | randomized-controlled-treatment | 1 |
560 | six-week-treatment | 1 |
561 | high-wnt | 1 |
562 | test-chart | 1 |
563 | 2-part | 39 |
564 | two-cohort | 9 |
565 | multicohort | 3 |
566 | longport | 1 |
567 | gene-of-interest | 1 |
568 | geneticist/oncologist | 1 |
569 | trpv1-antagonist | 1 |
570 | d2/d3-antagonist | 1 |
571 | neurolinguist | 1 |
572 | mmc/5-fu | 1 |
573 | arteries-iv | 1 |
574 | 5-w | 1 |
575 | westlaw | 1 |
576 | jew | 1 |
577 | q318x | 1 |
578 | no-mix | 1 |
579 | equinox | 3 |
580 | 78-day | 1 |
581 | head-mounted-display | 1 |
582 | midewanniquay | 1 |
583 | th1-pathway | 1 |
584 | busybody | 1 |
585 | semi-woody | 1 |
586 | vaccine-probe-study | 1 |
587 | pidgley | 1 |
588 | boggy | 1 |
589 | microtechnology | 2 |
590 | monarchy | 1 |
591 | chondrodystrophy | 1 |
592 | month/bimonthly | 1 |
593 | science.finally | 1 |
594 | woman.usually | 1 |
595 | post-test-only | 4 |
596 | post-only | 2 |
597 | trial.obviously | 1 |
598 | nonrandomized/partly | 1 |
599 | vulnery | 1 |
600 | task-battery | 1 |
601 | microbrewery | 1 |
602 | framework/theory | 1 |
603 | hypermigratory | 1 |
604 | cut-and-carry | 1 |
605 | staggered-entry | 2 |
606 | multi-country | 31 |
607 | multicountry | 20 |
608 | monomodality | 1 |
609 | lesser-quality | 5 |
610 | 20-community | 2 |
611 | 22-community | 1 |
612 | low-impulsivity | 1 |
613 | two-county | 23 |
614 | ectaz | 2 |
615 | 915-mhz | 1 |
616 | breathtron® | 1 |
617 | galactosyl-α | 1 |